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Introduction
Spinocerebellar ataxia type 3 (SCA3) is a late-onset neurological disorder and the most common autosomal dominant ataxia worldwide 1 . One of nine polyglutamine (polyQ) diseases, SCA3 is caused by a heterozygous CAG trinucleotide repeat expansion that produces an abnormally long, aggregate-prone polyQ sequence in the encoded disease protein 2 . In SCA3, this polyQ expansion occurs in ATXN3, a deubiquitinase with wide-ranging functions in the ubiquitin proteasome system, macroautophagy, DNA damage repair, and transcriptional regulation 1, 3 . Despite ubiquitous expression, polyQ-expanded ATXN3 inflicts neuronal dysfunction and loss in discrete brain nuclei spanning the brainstem, cerebellum, spinal cord, substantia nigra, diencephalon, and striatum through a presumed dominant toxic gain-offunction mechanism 4, 5 . There remains limited understanding of the pathogenic cascade leading to neurodegeneration, particularly in prodromal SCA3 stages, as well as a lack of wellsupported hypotheses for tissue-specific vulnerabilities, and no approved treatments to slow or stop progression of this fatal disease 1, 2 .
Disease-specific human pluripotent stem cell (hPSC) lines, including patient-derived induced pluripotent stem cell (iPSC) lines and human embryonic stem cell (hESC) lines derived from donated disease embryos, are proving to be increasingly important model systems for the study of neurodegenerative diseases 6, 7 . Disease-specific hPSC lines enable the study of disease processes in human disease-vulnerable differentiated cellular populations that express endogenous levels of pathogenic genes. In the past decade, several hPSC lines carrying the SCA3 mutation have been developed, including several SCA3 patient-derived iPSC lines [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and one hESC line harboring the SCA3 mutation 19 . This SCA3 hESC line, however, is not approved for research use in the United States. While the production of these lines represents progress towards improved human disease model systems, few or in some cases conflicting studies have been performed to verify that these developed SCA3 hPSC lines replicate well-established SCA3 molecular phenotypes. Identification of quantifiable, disease-dependent molecular phenotypes is arguably needed in order to use such SCA3 hPSC lines to investigate disease mechanisms or in preclinical testing of potential therapeutic agents for SCA3.
Here we report the validation and characterization of the first SCA3 disease-specific hESC line added to the NIH registry of approved hESC lines, designated UM134-1 on the NIH registry but referenced here as SCA3-hESC. In addition to confirming stem cell-like properties of undifferentiated SCA3-hESC, we evaluate well-established molecular phenotypes of SCA3 in undifferentiated stem cells and in differentiated neural progenitor cells and forebrain cortical neurons. We also demonstrate the potential for SCA3-hESC to serve as a disease model to facilitate preclinical drug development by assessing whether molecular phenotypes are rescued following treatment with an anti-ATXN3 antisense oligonucleotide (ASO) recently validated in preclinical SCA3 transgenic mouse studies 20, 21 . Together the findings support the SCA3-hESC line as an important new biological reagent for the SCA3 field, and establish its potential to improve human SCA3 disease modeling and preclinical drug assessment. 
Materials and Methods

Key Resource
RNA Isolation and Quantitative PCR.
Total RNA was isolated from cell lysates using Trizol reagent according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Reverse transcription was performed on 0.5-1μg of total RNA using the iScript cDNA synthesis kit according to the manufacturer's instructions (Bio-Rad, Hercules, CA). The cDNA was diluted 1:10 in nuclease-free water. iQ SYBR green quantitative polymerase chain reaction (qPCR) was performed on the diluted cDNA following the manufacturer's protocol (Bio-Rad). Average-adjusted relative quantification analysis was performed using human primers listed in Key resources table.
Immunoblotting.
Cell protein extracts were prepared from cells using two protocols. For immunoblot analysis of total protein extracts, cells were washed with cold PBS and lysed on ice with RIPA buffer containing complete mini protease inhibitor cocktail (Roche), followed by bath ultrasonication in chill water and centrifugation for total protein extract. For immunoblot analysis on soluble versus insoluble protein extracts, cells were washed and collected in PBS, bath ultrasonicated in chill water, centrifuged, and supernatants were collected (soluble fraction).
Remaining pellets were washed with PBS and resuspended in 1% sarkosyl in PBS containing complete mini protease inhibitor cocktail (Roche), vortexed for 30 sec and incubated at room temperature for 1 hr. Samples were bath ultrasonicated again for 5 min, centrifuged, and supernatants were collected (insoluble fraction to the mean control value indicated for each experiment, and expressed as % indicated control.
Immunocytochemistry and Image Analysis.
Cells were cultured on Poly-D-Lysine/Matrigel-coated coverslips. Cells were washed with cold PBS and then fixed with 4% paraformaldehyde (PFA) solution for 15 min on ice. Cells were permeabilized with 0.1% Triton X-100 for 5 min at room temperature then blocked in a 5%
Normal Goat Serum solution for 1 hr at room temperature. Cells were blocked in various primary antibodies overnight at 4°C. The cells were then immunostained with species-specific secondary antibodies conjugated to Alexa 488 or 568 fluorophores and mounted using Prolong Gold. Imaging was performed using an IX71 Olympus inverted microscope (Melville, NY) or Nikon-A1 confocal microscope (Melville, NY). All image analysis was performed using ImageJ analysis software (NIH, Bethesda, MD).
Electrophysiology
Electrophysiological recordings were performed on WT-and SCA3-CN plated on laminin-coated coverslips at 30-days post-differentiation. Cultured WT-or SCA3-CN were placed into a bath of room temperature Tyrode's solution 26 kHz in the fast-current clamp mode of the amplifier and filtered at 2 kHz. Spontaneous neuronal activity was recorded in whole-cell current clamp mode to observe characteristic action potential shape. Whole-cell voltage clamp recordings were used in order measure currents. WT-and SCA3-CN were held at -80 mV, and peak inward and outward currents were quantified in response to depolarizing current steps from -90 mV to +10 mV in +10 mV increments. Series resistance was compensated up to 40%. Cells were included if series resistance remained under 30 MΩ for the duration of the recording.
Statistics.
All statistical analyses were performed using Prism (7.0; Graph-Pad Software, La Jolla, CA). Quantified data represent the findings of three or more independent experiments. The statistical tests used are described in each figure legend. All error bars indicate variability about the mean expressed as standard error of the mean. Quantification of qRT-PCR transcript levels is normalized to mean WT-hESC, WT-NPC, or WT-CN transcript levels set at 1. Quantification of immunoblotted protein expression is normalized to mean WT-hESC, WT-NPC or WT-CN protein levels set at 100%. All tests set the level of significance at p < 0.05.
RESULTS
Derivation and characterization of SCA3-hESC line UM134-1
The SCA3-affected embryo was originally created by assistive reproductive technologies for the purpose of procreation. The embryo was donated to the University of Michigan following single gene preimplantation genetic testing, which identified the embryo as heterozygous for a pathogenic CAG repeat expansion in ATXN3. The derived UM134-1 hESC line (referred to here as SCA3-hESC) was accepted to the NIH registry of approved hESC lines in 2014 (#0286). The unrelated hESC line UM4-6 (#0147, referred to here as WT-hESC), developed previously under the same protocol at the University of Michigan and also accepted to the NIH registry, was used throughout these studies as a comparative control 22 .
Undifferentiated SCA3-hESC exhibited a cellular morphology characteristic of pluripotent stem cells and express pluripotency markers OCT3/4, SOX2 and NANOG ( Figure 1A) .
Quantitative real-time PCR (qRT-PCR) confirmed that SCA3-hESC express pluripotency markers LIN28, OCT4, SOX2, and NANOG transcripts at levels comparable to WT-hESC ( Figure 1B ) (n = 3 passages). Following 21 days of differentiation, PCR analysis confirmed that SCA3-hESC derived embryoid bodies express lineage markers AFP (endoderm), BRACHYURY (mesoderm), and TUJ-1 (ectoderm) ( Figure 1C ). G-banded cytogenetic analysis of SCA3-hESC identified a normal 46,XY karyotype with no chromosomal abnormalities ( Figure 1D ). A previous study showed that the WT-hESC line used here also has a normal 46,XY karyotype with no chromosomal abnormalities 22 .
Immunoblot analysis of WT-and SCA3-hESC protein extracts using monoclonal antibody 1C2, which recognizes expanded polyQ, revealed a band of ~60 kDa in SCA3-hESC that is not present in WT-hESC, indicating expression of a polyQ-expanded protein in SCA3-hESC ( Figure 1E ). Anti-ATXN3 immunoblot analysis identified a doublet of ~42-44 kDa in WT-hESC consistent with normal repeat length polymorphism in ATXN3, whereas ATXN3 bands of ~42kDa and ~60kDa were observed in SCA3-hESC, corresponding to wild type ATXN3 (wtATXN3) and polyQ-expanded mutant ATXN3 (mutATXN3), respectively ( Figure 1F ).
Subsequent gene fragmentation analysis performed on early passages of both lines confirmed that SCA3-hESC is heterozygous for one pathogenic and one normal ATXN3 allele encoding ATXN3 polyQ expansions of 70Q and 13Q, respectively, compared to non-pathogenic WT-hESC polyQ lengths of 22Q and 13Q ( Figure 1G ).
Undifferentiated SCA3-hESC exhibit ATXN3 aggregation and nuclear sequestration.
Misfolding of expanded polyQ proteins and subsequent accumulation as high molecular weight oligomers and aggregates is a key pathological feature of polyQ diseases 4, 27, 28 . SCA3 post-mortem patient brains and transgenic mouse models of SCA3 exhibit widespread neuronal intranuclear and cytosolic inclusions of ATXN3 in brain regions affected in disease [28] [29] [30] [31] [32] .
Aggregation of polyQ-expanded mutATXN3 has been detected in cellular models, but to our knowledge only with the aid of genetic or environmental manipulations, such as overexpression of highly aggregate-prone ATXN3 fragments [33] [34] [35] or stress induction through proteasomal inhibition or excitotoxicity 12, 36 . A human cell model showing aggregation of mutATXN3 expressed at endogenous levels in the absence of exogenous stressors would be an excellent tool for advancing our understanding of the role of native ATXN3 misfolding and aggregation in SCA3 pathogenesis.
We first sought to determine whether SCA3-hESC recapitulated mutATXN3 misfolding and aggregation under normal culture conditions. Anti-ATXN3 immunoblot analysis of undifferentiated WT-and SCA3-hESC protein lysates demonstrated accumulation of high molecular weight (HMW) ATXN3 species in SCA3-hESC that was largely absent in WT-hESC ( Figure 2A ). Quantification confirmed an 80% ± 21% increase in HMW ATXN3 species >100kDa
in SCA3-hESC relative to WT-hESC (p = 0.02, n = 3 passages) ( Figure 2B ). Anti-ATXN3 immunocytochemistry (ICC) with DAPI co-staining revealed striking intranuclear and cytoplasmic ATXN3-positive puncta of variable sizes and shapes in SCA3-hESC ( Figure 2C ).
Though rare puncta were observed in WT-hESC, SCA3-hESC formed significantly more puncta, averaging ~1 per cell with many cells containing multiple puncta (SCA3-hESC = 0.93 ± 0.12 ATXN3 puncta/cell, WT-hESC = 0.04 ± 0.01 ATXN3 puncta/cell, p<0.0001, n = 3-4 passages, 3-5 confocal images/passage) ( Figure 2C and 2D).
Abnormal sequestration of ATXN3 into neuronal nuclei is also a prominent pathological feature of SCA3 human disease 28, [37] [38] [39] . Possessing both nuclear export and nuclear localization sequences, non-pathogenic ATXN3 is normally diffusely localized throughout the cytosol and nucleus 39 , but undergoes rapid nuclear translocation following induction of proteotoxic stress 36 .
Though it remains unclear why polyQ-expanded mutATXN3 becomes sequestered in neuronal nuclei, preventing or decreasing nuclear import of mutATXN3 rescues disease in SCA3 transgenic mouse models, suggesting that nuclear localization of mutATXN3 is a necessary step in disease pathogenesis 37 . To determine whether SCA3-hESC replicate this key pathological hallmark of disease, we quantified mean ATXN3 nuclear integrated density in undifferentiated WT-and SCA3-hESC, employing anti-ATXN3 and DAPI co-stained confocal imaging. Subsequent ImageJ analysis revealed an over 25% increase in mean ATXN3 nuclear integrated density in SCA3-hESC relative to WT-hESC (p < 0.0001) ( Figure 2C and 2E) . Thus, in contrast to previously reported SCA3 in vitro models 12,33-36 , SCA3-hESC endogenously form nuclear and cytoplasmic ATXN3 inclusions and exhibit enhanced nuclear sequestration of ATXN3 under normal, unstressed culture conditions.
Large ATXN3 aggregates localize to p62 + aggresomes in SCA3-hESC.
To further characterize observed ATXN3 + puncta, we investigated whether proteins typically co-localizing with aggregates in SCA3 patient brains similarly co-localize in SCA3-hESC. The ubiquitin-binding shuttle protein p62 is found in ubiquitinated protein aggregates in many neurodegenerative diseases 40 , including ATXN3 aggregates in SCA3 patient post-mortem brains 30, 41, 42 . Confocal imaging was performed on undifferentiated WT-and SCA3-hESC following anti-p62 and anti-ATXN3 immunofluorescence and DAPI staining ( Figure 2C ). Unlike WT-hESC, in which p62 was more diffuse throughout cells and formed few p62+ puncta, SCA3-hESC formed large, juxtanuclear p62 + puncta: SCA3-hESC = 0.72 ± 0.13 p62 puncta/cell; WT-hESC = 0.10 ± 0.02 p62 puncta/cell (p < 0.0001) ( Figure 2C and 2F ). Large p62 + structures always co-localized with large ATXN3 + puncta ( Figure 2C ), although many ATXN3 + puncta lacked p62-staining suggesting there are two or more ATXN3 inclusion states in SCA3-hESC. In addition, p62 exhibited significantly increased localization to the nucleus in SCA3-hESC (mean p62 nuclear integrated density: SCA3-hESC = 58065 ± 1141; WT-hESC = 45332 ± 743, p <0.0001). Previous studies have shown that inhibiting autophagy induces p62 nuclear sequestration, thus enhanced nuclear p62 may indicate autophagic impairment in SCA3-hESC 43 .
Notably, p62 promotes the formation of mutATXN3 aggresomes in cell-based overexpression model systems 44 . Aggresomes are dynamic pericentriolar structures consisting of a condensed protein aggregate core contained within an intermediate filament vimentin cage that function as a cellular pathway to consolidate misfolded protein aggregates 45 . Anti-vimentin and anti-ATXN3 ICC was performed on WT-and SCA3-hESC to investigate the possibility of aggresome formation in SCA3-hESC. SCA3-hESC formed distinct vimentin + puncta that consistently coincided with large ATXN3 + puncta ( Figure 2G ). Like p62, vimentin + puncta were rarely observed in WT-hESC, and when present did not preferentially co-localize with ATXN3
(data not shown). Further ICC investigations revealed that the 26S proteasome subunit PSMD11 also selectively localized to ATXN3 puncta in SCA3-hESC, demonstrating that components of the ubiquitin-dependent protein quality control machinery are also being sequestered into aggregates in SCA3-hESC ( Figure 2H ). Together, these results suggest SCA3-hESC, but not WT-hESC, form ATXN3 aggregates, the majority of which are consolidated into p62 + aggresomes.
Altered expression of key protein clearance pathway proteins in SCA3-hESC.
Aggresome formation suggests a failure of canonical degradation pathways to dispose of misfolded proteins 45 . To determine which pathways may contribute to aggresome formation in SCA3-hESC, we evaluated key proteins involved in protein homeostasis including markers for autophagy, ubiquitin-dependent proteasomal degradation and protein folding. The autophagylinked protein p62 is selectively degraded through autophagic clearance and thus increased levels of p62 may indicate autophagic inhibition 46 . Immunoblot analysis showed that p62 levels were increased by 80% ± 24% in SCA3-hESC compared to WT-hESC (p = 0.008, n = 3 passages per line, 2-3 replicates per passage) ( Figure 3A and 3B ). HMW p62, which is presumably aggregated, also accumulated in SCA3-hESC protein lysates, likely corresponding to p62 interactions with insoluble aggresome complexes formed by mutATXN3 ( Figure 3A and   3B ). The expression of autophagy-related proteins Beclin1 and LC3-II was also compared in WT-and SCA3-hESC protein lysates ( Figure 3C ). Though variable, LC3-II protein levels were significantly decreased by 64% ± 26% in SCA3-hESC relative to WT-hESC (p = 0.037),
whereas Beclin1 levels did not statistically differ (p = 0.57) (n = 3 passages per line, 2-3 replicates per passage) ( Figure 3D ).
Increased levels of ubiquitinated substrates have been observed in human SCA3 brain tissue and mouse models of SCA3, possibly reflecting altered mutATXN3 deubiquitinase activity 47 and downstream impairment in proteolytic clearance pathways 48, 49 . Using a panubiquitin antibody, we found that poly-ubiquitinated protein levels were slightly but significantly increased by 17% ± 4% in SCA3-hESC relative to WT-hESC (p = 0.015, n = 3 passages per line) ( Figure 3E and 3F ), suggesting impairment in ubiquitin-dependent proteasomal clearance.
Heat shock proteins Hsp40, Hsp70, and Hsp90β, which play important roles in maintaining protein homeostasis in cells 50 , are also altered in SCA3 post-mortem brains and disease model systems [50] [51] [52] [53] . Immunoblot analysis revealed Hsp40 and Hsp70 to be significantly decreased by 50% ± 21% (p = 0.037) and 42% ± 18% (p = 0.039), respectively, in SCA3-hESC relative to WT-hESC (n = 3 passages per line, 2-3 replicates per passage) ( Figure 3G and 3H ). SCA3-hESC also consistently exhibited a doublet band for Hsp70 that was absent from WT-hESC, which could indicate altered post-translational modifications, splicing, or protein-protein interactions of Hsp70 in SCA3-hESC. Hsp90β also trended towards decreased levels in SCA3-hESC, but failed to reach statistical significance (p = 0.054) ( Figure 3G and 3H) . Though further analysis is required to determine the extent and exact nature of autophagic and proteasomal dysfunction in SCA3-hESC, the altered levels of key regulators of protein quality control spanning autophagy, ubiquitin-dependent proteasomal degradation and protein folding machinery suggest widespread disruption of protein clearance in SCA3-hESC, a characteristic feature of SCA3 pathogenesis 1 .
ASO-mediated ATXN3 reduction rescues aggresome formation in SCA3-hESC.
To assess the potential of SCA3-hESC as a cellular model for preclinical therapeutic testing, we investigated whether delivery of an anti-ATXN3 antisense oligonucleotide (ASO)
recently validated in preclinical studies 20,21 could rescue molecular phenotypes in SCA3-hESC.
ASOs are short, chemically modified nucleotide sequences that, when bound to sequencespecific target mRNA, activate RNaseH-mediated degradation of the targeted mRNA thereby reducing expression of the encoded protein 54 . In preclinical studies, we recently demonstrated that a single intracerebroventricular injection of an anti-ATXN3 ASO into a transgenic mouse model of SCA3 suppressed expression of mutATXN3, reduced neuronal nuclear ATXN3 accumulation, and rescued several molecular, electrophysiological, and behavioral phenotypes in SCA3 mice 20, 21 .
WT-and SCA3-hESC were transfected with 100 nM or 500 nM anti-ATXN3 ASO (referred to previously as ASO-5 20,21 ), a non-specific ASO control (ASO-Ctrl) or PBS vehicle, then harvested three or four days later for RNA and protein analysis, respectively. Immunoblot analysis identified a significant decrease in both wtATXN3 and mutATXN3 protein levels in SCA3-hESC transfected with 100 nM and 500 nM compared to vehicle-treated or ASO-Ctrl treated SCA3-hESC groups [500 nM: wtATXN3 = 63% ± 8%, (p = 0.0003); mutATXN3 = 70% ± 7% (p = 0.0015)], normalized to vehicle-treated SCA3-hESC set at 100%, n = 6 replicates per treatment group] ( Figure 4A ). qRT-PCR analysis confirmed an approximately 75% reduction in total ATXN3 transcript levels in SCA3-hESC transfected with 500 nM ASO relative to vehicletreated SCA3-hESC (p = 0.03, n = 3) ( Figure 4B ). SCA3-hESC transfected with 100 nM ASO trended towards decreased ATXN3 expression levels at 72 hours, but failed to reach significance (p = 0.09, n = 3 replicates per treatment group) ( Figure 4B ).
To determine whether ASO treatment rescued ATXN3 aggregation and p62 + aggresome formation, we performed anti-ATXN3 and anti-p62 ICC on SCA3-hESC transfected with 500 nM ASO compared to vehicle-treated WT-and SCA3-hESC ( Figure 4C ). Four days after transfection, diffuse and punctate ATXN3 fluorescence was visibly reduced in ASO-treated SCA3-hESC relative to vehicle-treated SCA3-hESC ( Figure 4C ). Importantly, ASO-mediated reduction in ATXN3 markedly reduced ATXN3 puncta per cell in SCA3-hESC to levels nonstatistically different from that of WT-hESC (vehicle-treated WT-hESC = 0.21 ± 0.07 ATXN3 puncta/cell, vehicle-treated SCA3-hESC = 1.28 ± 0.33 ATXN3 puncta/cell, ASO-treated SCA3-hESC = 0.43 ± 0.15 ATXN3 puncta/cell, n = 3 replicates per treatment group, 2-3 confocal images per replicate) ( Figure 4C and 4D) . Similarly, ASO treatment led to visibly reduced diffuse p62 and completely rescued mean p62 puncta per cell four days after ASO transfection (vehicle-treated WT-hESC = 0.05 ± 0.02 p62 puncta/cell, vehicle-treated SCA3-hESC = 0.85 ± 0.12 p62 puncta/cell, ASO-treated SCA3-hESC = 0.30 ± 0.09 p62 puncta/cell, p<0.0001, n = 3
replicates per treatment group, 2-3 confocal images per replicate) ( Figure 4C and 4E) .
In summary, non-allele specific suppression of ATXN3 with an anti-ATXN3 ASO rescued ATXN3 aggregation and p62 + aggresome formation in SCA3-hESC despite achieving a relatively modest 30% reduction in soluble mutATXN3 protein. These findings support the view that these disease-relevant molecular phenotypes are caused by expression of the pathogenic disease protein and do not reflect non-specific hESC line variations between WT-and SCA3-hESC. The identification of aggresome formation as a disease-dependent, reversible molecular phenotype bolsters its potential as a disease biomarker and the potential utility of this line for therapeutic preclinical testing for SCA3.
SCA3-hESC can be differentiated into neural progenitor cells and MAP2 + cortical neurons.
As a degenerative brain disease 1 , SCA3 is thought principally to involve neurons. Thus, studying the disease in human neuronal cultures harboring the endogenous causative mutation should provide biologically relevant insights into disease. WT-and SCA3-hESC were differentiated into neural progenitor cells (NPC) and cortical neurons (CN) at similar efficiencies using a previously described protocol 25 . qRT-PCR analysis confirmed loss of pluripotency marker OCT4 and gain of neural lineage marker NESTIN in derived NPC and 30-days postdifferentiation (Day 30) CN, with similar NESTIN transcript levels achieved in both WT-and SCA3-NPC ( Figure 5A and 5B ). In addition, differentiated WT-and SCA3-CN expressed mature neuronal marker MAP2 at similar levels 30-days post-differentiation ( Figure 5C ). ICC analysis confirmed expression of the neural lineage marker NESTIN in derived SCA3-NPC ( Figure 5D ) and the mature neuronal marker MAP2 in differentiated SCA3-CN ( Figure 5E ).
To further characterize neuronal maturation, we performed whole-cell electrophysiological recordings of Day 30 WT-and SCA3-CN. In current clamp mode, we observed spontaneous neuronal firing with characteristic action potential shape in SCA3-CN 30days post-differentiation ( Figure 5F ). Voltage-clamp recordings of WT-and SCA3-CN indicated both inward and outward currents in response to depolarizing voltage steps with no statistical difference between WT-and SCA3-CN peak inward current [F (1, 14) =0.19, p=0.67] or peak outward current [F(1,14) =0.66, p=0.43] (Figure 5G-5I) . These data suggest proper maturation of derived WT-and SCA3-CN into MAP2-positive neurons that exhibit firing properties, with no indication of impaired neuronal differentiation of SCA3-hESC.
Robust ATXN3 aggregation in SCA3-hESC derived neural progenitor cells and cortical neurons.
After confirming NPC and CN differentiation, we evaluated ATXN3 expression and aggregation propensity in derived SCA3-NPC and SCA3-CN. Soluble wtATXN3 and mutATXN3
were expressed in differentiated SCA3-NPC and Day 30 SCA3-CN at the expected molecular weights ( Figure 6A and 6C ). Similar to SCA3-hESC, SCA3-NPC and SCA3-CN exhibited markedly increased accumulation of HMW ATXN3. Quantified HMW ATXN3 levels were about 2.5 times greater in SCA3-NPC relative to WT-NPC (p < 0.001) ( Figure 6A and 6B) and 1.7 times greater in SCA3-CNs relative to WT-CNs (p = 0.003) ( Figure 6C and 6D) .
We then performed anti-ATXN3 ICC with DAPI counter-stain on NPC and Day 30 CN differentiated from WT-and SCA3-hESC. Whereas ATXN3 was diffusely expressed throughout the nucleus and cytoplasm in WT-NPC, ATXN3 in SCA3-NPC localized to numerous cytoplasmic aggregates that varied in size, shape, number and location ( Figure 6E ).
Differentiated SCA3-CN also exhibited robust ATXN3 inclusion formation, with individual neurons frequently forming one or more large, round, juxtanuclear ATXN3-positive inclusions as well as occasional round inclusions in distal processes ( Figure 6F ). By contrast, inclusions were rarely observed in WT-NPC or WT-CN. Unlike the case in SCA3-hESC, enhanced nuclear accumulation of ATXN3 was not observed in SCA3-NPC or SCA3-CN. These data demonstrate robust aggregation when mutATXN3 is expressed in SCA3-hESC, -NPC, and -CN under normal culture conditions in the absence of applied stressors, which has not been described in any other SCA3 disease-specific iPSC or hESC line.
Altered expression of key protein clearance pathway proteins in SCA3-CN.
We also analyzed whether the dysregulation of components of the protein homeostasis machinery observed in undifferentiated SCA3-hESC persisted in Day 30 SCA3-CN. WT-and SCA3-CN were fractionated into Triton-X100 soluble and insoluble protein extracts which were then subjected to immunoblot analysis. Soluble p62 levels were significantly increased by 69 ± 21% in SCA3-CN relative to WT-CN (p = 0.03), and the ratio of insoluble to soluble p62 protein was more than doubled in SCA3-CN (p = 0.02) ( Figure 7A and 7B) . Thus, similar to SCA3-hESC, SCA3-CN exhibit increased p62 expression with some of it likely sequestered into insoluble ATXN3 + aggregates. Immunoblot analysis of the autophagy proteins Beclin1 and LC3 was also performed on unfractionated protein lysates from WT-and SCA3-CN. Beclin1 levels trended towards decreased levels but failed to reach statistical significance (p = 0.07), and LC3-II levels were unchanged in SCA3-CN relative to WT-CN (p = 0.72) ( Figure 7C and 7D) .
Therefore, while SCA3-hESC and SCA3-CN both exhibit markers suggesting impaired autophagy, the observed differences suggest mutATXN3 may interact and interfere with autophagic pathways differently in undifferentiated hESC versus differentiated neurons.
Additional components of the protein homeostasis machinery were evaluated in SCA3versus WT-CN. Anti-ubiquitin immunoblot analysis revealed no difference in total soluble or insoluble poly-ubiquitinated substrates in protein extracts from the two lines ( Figure 7C and 7D ).
There was, however, a significant increase in the level of short ubiquitin chains [(Ub) [2] [3] [4] partitioning in the insoluble fraction in SCA3-CN: a 54% ± 20% increase relative to WT-CN (p = 0.05) ( Figure 7E and 7F) . As in SCA3-hESC, Hsp70 levels were significantly decreased in unfractionated SCA3-CN relative to WT-CN (decreased by 44% ± 15%; p = 0.048) ( Figure 7G and 7H). In contrast, Hsp40 and Hsp90β levels did not statistically differ between the two lines (p = 0.32 and p = 0.60, respectively) ( Figure 7G and 7H) . Overall, SCA3-CN exhibited significant changes in several markers of autophagy, ubiquitin-dependent proteasomal clearance, and protein folding. Several disease-specific changes in SCA3-CN mirrored those seen in undifferentiated SCA3-hESC while others did not, suggesting cell-type specific differences in the interaction of mutATXN3 with components of protein homeostasis.
Discussion
We SCA3-hESC presumably can express all ATXN3 isoforms generated from the endogenous human disease gene and, as demonstrated here, recapitulates aggregation and nuclear sequestration of mutATXN3. Thus, SCA3-hESC is well suited to assess compounds aimed at reducing mutATXN3 protein, preventing aggregation, or altering subcellular localization of mutATXN3. Here we performed a proof-of-concept assessment of a previously validated gene silencing therapy 20, 21 ; specifically, we demonstrated that ASO-mediated reduction of ATXN3 mitigates aggresome formation in SCA3-hESC. The ability to use tools such as ASOs to modify disease-relevant phenotypes supports the hypothesis that at least some of the observed molecular phenotypes are directly attributable to mutATXN3 expression, and could enable future mechanistic studies of disrupted pathways in SCA3. However, we cannot rule out the possibility that some of the observed molecular phenotypes in SCA3-hESC and differentiated cell types are due to cell line-specific variations not directly resulting from expression of mutATXN3. Future studies using this novel cell line would benefit from development of genetically corrected isogenic control lines from SCA3-hESC, such as those that have been developed from Huntington's disease iPSC lines 57 . In addition, the SCA3 field would benefit from the creation of more SCA3 hESC lines, which may occur due to increased numbers of patients choosing in vitro fertilization with preimplantation genetic testing for monogenic and repeat expansion disorders.
We also observed the formation of high molecular weight ATXN3 aggregates throughout neuronal differentiation, including in derived SCA3-NPC and mature SCA3-CN. Though there is evidence for involvement of the frontal, parietal, temporal, occipital and limbic lobes in SCA3 58, 59 , the degree of neuronal loss in these regions is significantly less severe than in brainstem and cerebellar nuclei 60 . Because cortical regions likely play less of a role in the progressive deterioration of motor control in SCA3 patients, differentiated forebrain cortical neurons may not be the best cellular model in which to study SCA3 disease processes.
Dopaminergic neurons in the substantia nigra, however, are highly affected and exhibit significant degeneration in SCA3 human brains. Future studies could take advantage of the wealth of improved dopaminergic differentiation protocols 61 to assess specific differences in pathology and neuronal vulnerability in disease-affected dopaminergic versus disease-spared cortical neuronal populations. In addition, SCA3 research to date has been neuron-centric, meaning that little is known about glial involvement in disease progression. Recent studies demonstrating significant transcriptional and protein expression changes in glial-enriched genes [62] [63] [64] and altered glial morphology and density in affected brain regions with disease progression 4,65 point to the need for glial-focused investigations in SCA3. The pluripotent potential of SCA3-hESC in combination with the detection of native mutATXN3 aggregation demonstrated here, could prove invaluable for future studies of cell-type specific differences in ATXN3 function, aggregation propensity and vulnerability to aggregation-induced cellular insults.
Conclusions
Here we have presented a novel hESC line that expresses the endogenous SCA3 human disease protein. We have verified the pluripotent potential of the SCA3-hESC line, and that it can be directed to differentiated into mature, electrophysiologically active neurons. Most importantly, we have identified robust, well-established and mutATXN3-dependent pathogenic features of SCA3 human disease in undifferentiated stem cells and throughout neuronal differentiation. Based on these studies, we believe the SCA3-hESC line holds strong promise to advance our understanding of SCA3 disease mechanisms, enable future investigations into celltype specific contributions to disease and improve preclinical development of SCA3 therapies. 
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